FIELD: medicine.
SUBSTANCE: invention relates to immunology. Described is a method for determining and quantifying specific cellular immunity to SARS-CoV-2 virus N-protein antigens.
EFFECT: developing a simple and convenient method for determining and assessing specific cellular immunity to antigens of the N-protein of the SARS-CoV-2 virus, which enables to quantitatively determine the specific cellular component of the immune response to this virus.
1 cl, 1 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING AND QUANTIFYING SPECIFIC CELLULAR IMMUNITY TO SARS-CoV-2 VIRUS S-PROTEIN ANTIGENS | 2021 |
|
RU2762616C1 |
| METHOD FOR DETERMINING THE SPECIFIC CELLULAR IMMUNE RESPONSE TO CORONAVIRUS ANTIGENS (SARS-CoV-2) | 2021 |
|
RU2780369C1 |
| METHOD FOR DETERMINING SPECIFIC CELL IMMUNE RESPONSE TO MEASLES AND RUBELLA VIRUS ANTIGENS | 2011 |
|
RU2464571C1 |
| METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES | 2021 |
|
RU2760438C1 |
| METHOD OF PREDICTING COMPLICATIONS AFTER COVID-19 IN PERSONS WITH COMORBID BACKGROUND IN THE ARCTIC REGION | 2023 |
|
RU2812780C1 |
| RECOMBINANT VIRUS-LIKE PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 | 2021 |
|
RU2769224C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| BISPECIFIC MONOCLONAL ANTIBODY AGAINST SARS-COV-2 | 2022 |
|
RU2791749C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV-UB IMMUNOGEN PROTEIN, RECOMBINANT PLASMID DNA PBSI-COV-UB, WHICH ENSURES THE EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL POLYEPITOPE BSI-COV-UB IMMUNOGEN PROTEIN CONTAINING UBIQUITIN AND EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806590C1 |
| VIRUS-LIKE CHIMERIC PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 CONTAINING CORONAVIRUS AND ROTAVIRUS PROTEINS | 2022 |
|
RU2779810C1 |
